Table 3.
Pre-operative | 12 Weeks Post-operative | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
YBT-LQ Composite | Quadriceps Strength | Normalized ANT | YBT-LQ Composite | Quadriceps Strength | Normalized ANT | |||||||||
Involved | Uninvolved | Involved | Uninvolved | Involved | Uninvolved | Involved | Uninvolved | Involved | Uninvolved | Involved | ||||
Pre-operative | YBT-LQ Composite | Uninvolved | 0.732** | |||||||||||
Quadriceps Strength | Involved | 0.119 | 0.770** | |||||||||||
Uninvolved | −0.101 | −0.098 | 0.820** | |||||||||||
Normalized ANT | Involved | 0.806** | 0.578** | −0.093 | −0.319 | |||||||||
Uninvolved | 0.588** | 0.691** | −0.226 | −0.356 | 0.705 | |||||||||
12 Weeks Post-operative | YBT-LQ Composite | Involved | 0.660** | 0.534** | 0.189 | −0.050 | 0.505** | 0.335** | ||||||
Uninvolved | 0.489** | 0.601** | 0.043 | −0.136 | 0.399** | 0.427** | 0.852** | |||||||
Quadriceps Strength | Involved | −0.136 | −0.089 | 0.772** | 0.664** | −0.264 | −0.295 | 0.167 | 0.093 | |||||
Uninvolved | −0.200 | −0.118 | 0.804** | 0.855** | −0.378** | −0.396** | −0.024 | −0.094 | 0.818** | |||||
Normalized ANT | Involved | 0.433** | 0.390** | 0.168 | −0.050 | 0.524** | 0.398** | 0.738** | 0.569** | 0.188 | −0.017 | |||
Uninvolved | 0.314 | 0.528** | −0.053 | −0.176 | 0.440** | 0.612** | 0.546** | 0.712** | 0.060 | −0.151 | 0.717** |
indicates statistical significance, p<0.05.